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Summary
Sézary syndrome (SS) is a rare, leukemic type of cutaneous T-cell lymphoma (CTCL), for which extra-
corporeal photopheresis (ECP) is a first-line therapy. Reliable biomarkers to objectively monitor the 
response to ECP in patients with SS are missing. We examined the quantitative and qualitative impact 
of ECP on natural killer (NK) cell activity in SS patients, and especially their functional ability for antibody- 
dependent cell-mediated cytotoxicity (ADCC). Further, we addressed the question whether the magni-
tude of the effect on ADCC can be associated with the anti-cancer efficacy of ECP in SS patients. We 
assessed numbers of NK cells, ADCC activity, and treatment response based on blood tumor staging in 
a cohort of 13 SS patients (8 women, 5 men) treated with ECP as a first-line therapy. Blood samples were 
collected before treatment start and after an average of 9 months of uninterrupted ECP treatment. NK cell 
numbers were reduced in SS patients compared to healthy individuals and showed a tendency of recovery 
after long-term ECP treatment, independent of the clinical response to treatment. Patients with marginal 
increase (≤1.5 AU-fold) or lack of increase in ADCC activity failed to respond clinically to treatment, while 
patients with an increased ADCC activity showed a reduction in blood tumor burden. NK-mediated ADCC 
is selectively enhanced and might be a mechanism underlying the effect of ECP while in addition it can 
possibly serve as a reliable biomarker to objectively monitor response to ECP in patients with SS.
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Sézary syndrome (SS) is a rare leukemic type of cutaneous 
T-cell lymphoma (CTCL) representing around 5% of all 
CTCL cases.1,2 SS typically manifests with a triad of erythro-
derma, generalized lymphadenopathy, and the presence of 
malignant T cells in the skin, lymph nodes, and peripheral 
blood, morphologically presenting with “cerebriform” 
nuclei.3,4 Numerous immune abnormalities have been 
described in SS patients, most commonly reported among 
those are the increased secretion of immunosuppressive Th2 
cytokines and the decreased proinflammatory Th1-mediated 
immune response.5–7 These alterations lead to global immu-
nosuppression and increased susceptibility to infections which 
are a leading cause of death in SS patients.8 Therefore, ther-
apeutic approaches that aim at immune modulation are stan-
dard therapies in SS. Currently, extracorporeal photophoresis 
(ECP) and administration of interferon-α, are established and 
recommended first-line immunomodulatory treatment 
options in SS.1 ECP is a leukapheresis-based therapy, where 
the patient’s lymphocytes are collected and exposed to meth-
oxsalen followed by ultraviolet A light, before being reinfused 
to the patient. ECP is nowadays available in more than 200 
centers worldwide with cited response rates for CTCL of 
approximately 60% and complete responses of 14–26%.9,10 
ECP is used as a monotherapy or in combination with other 
immunomodulatory agents, and is well-tolerated.10,11 Given 
the interpatient variability of reponse to ECP, the identification 
of factors associated with a positive response to ECP at baseline 
is of great interest.
In this work, we aimed to answer the question whether ECP 
influences the number of NK cells and the efficacy of NK- 
mediated antibody-dependent cellular cytotoxicity (ADCC). 
ADCC is an adaptive immune response, where Fc receptor- 
bearing NK cells recognize and kill antibody-coated target cells 
by releasing cytotoxic molecules, such as perforin and gran-
zymes. Furthermore, we aimed to explore if the magnitude of 
ADCC can be associated with the treatment response in SS 
patients.
Materials and methods
Patients and collection of primary human samples
13 patients newly diagnosed with Sézary syndrome between 
2012 and 2019 treated with ECP as a first-line systemic mono-
therapy with at least 1.5 months clinical follow-up after the 
start of the ECP therapy were included in a single-center, 
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retrospective, cohort study (Table 1). Diagnosis of Sézary syn-
drome was established according to the criteria of the World 
Health Organization–European Organization for Research and 
Treatment of Cancer and the International Society for 
Cutaneous Lymphomas.4,12 ECP treatment was performed 
using the closed photopheresis apparatus “CELLEX” 
(Mallinckrodt Pharmaceuticals, USA). Treatment schedule fol-
lowed the European dermatology forum-guidelines on the use 
of extracorporeal photophoresis, with one ECP cycle (on two 
consecutive days) every 2 weeks for the first 3 months, followed 
by one ECP cycle every 4 weeks.9 The peripheral blood samples 
were collected during routine ECP procedure right before the 




















Responder (N) ECP stopped/continued
1 1 SS stage IVA1 F CD4:CD8 47.5 2.1 CR R stopped due to remission
T4N1M0B2 CD4+ CD26-/CD7- (cells/µl) 6605 158
CD4+ CD26-/CD7- (%) 97 40
Blood stage B2 B0
2 - SS stage IVA1 F CD4:CD8 82 93 SD N stopped due to death
T4N1bM0B2 CD4+ CD26-/CD7- (cells/µl) 582 1202
CD4+ CD26-/CD7- (%) 51 45
Blood stage B1 B2
3 3 SS stage IVA1 F CD4:CD8 47.5 47.5 PR R stopped due to patients’ wish
T4N0M0B2 CD4+ CD26-/CD7- (cells/µl) 9790 4736
CD4+ CD26-/CD7- (%) 93 44
Blood stage B2 B2
4 4 SS stage IVA1 M CD4:CD8 15.2 8.4 PR R stopped due to inclusion in
T4NxM0B2 CD4+ CD26-/CD7- (cells/µl) 4657 1243 clinical trial
CD4+ CD26-/CD7- (%) 72 73
Blood stage B2 B2
5 5 SS stage IVA1 F CD4:CD8 48 47.5 SD N stopped due to lost to follow 
up
T4NxM0B CD4+ CD26-/CD7- (cells/µl) 11135 5939
CD4+ CD26-/CD7- (%) 94 94
Blood stage B2 B2
6 6 SS stage IVA1 F CD4:CD8 4.6 8.2 SD N continued (since 4.5 years)
T4NxM0B CD4+ CD26-/CD7- (cells/µl) 989 1540
CD4+ CD26-/CD7- (%) 49 81
Blood stage B1 B2
7 7 SS stage IVA1 F CD4:CD8 1.1 1.9 SD N stopped due to lost to follow 
up
T4NxM0B2 CD4+ CD26-/CD7- (cells/µl) 346 381
CD4+ CD26-/CD7- (%) 57 64
Blood stage B1 B1
8 8 SS stage IVA1 F CD4:CD8 44.2 31 SD N stopped due to inclusion in
T4NxM0B2 CD4+ CD26-/CD7- (cells/µl) 3556 5424 clinical trial
CD4+ CD26-/CD7- (%) 92 96
Blood stage B2 B2
9 9 SS stage IVA1 M CD4:CD8 6.8 5 CR R continued (since 1.5 years)
T4N0M0B2 CD4+ CD26-/CD7- (cells/µl) 1529 226
CD4+ CD26-/CD7- (%) 78 39
Blood stage B2 B0
- 10 SS stage IVA1 F CD4:CD8 10.4 48.5 SD N continued, plus additonal
T4N1M0B2 CD4+ CD26-/CD7- (cells/µl) 1923 3876 therapy with MTX
CD4+ CD26-/CD7- (%) 77 86
Blood stage B2 B2
- 11 SS stage IVA1 M CD4:CD8 14.3 7.3 PR R continued (since 4 years)
T4N1M0B2 CD4+ CD26-/CD7- (cells/µl) 2356 541
CD4+ CD26-/CD7- (%) 91 59
Blood stage B2 B1
- 12 SS stage IVA2 M CD4:CD8 1.5 1.2 SD N continued (since 3 years)
T4N3M0B2 CD4+ CD26-/CD7- (cells/µl) 900 1451
CD4+ CD26-/CD7- (%) 73 64
Blood stage B1 B2
- 13 SS stage IVA1 M CD4:CD8 1.1 2 SD N stopped due to death
T4N0M0B2 CD4+ CD26-/CD7- (cells/µl) 133 90
CD4+ CD26-/CD7- (%) 46 61
Blood stage B0 B0
MTX: Methotrexate 
Responder: CR, PR 
Non-responder: SD, PD 
SS: Sezary Syndrome 
ECP: Extracorporeal photopheresis 
CR: complete response 
PR: partial response 
SD: stable disease 
PD: progressive disease
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initiation of ECP treatment and on average after 9 months of 
uninterrupted ECP treatment. In detail, 69.2% (9/13) of the 
baseline pre-ECP samples were collected within 2 days before 
ECP initiation, 30.7% (4/13) samples were collected at 
a median of 2.5 months (range 1–7) before therapy start. 
61.5% (8/13) of the post-ECP samples were collected after 
a median of 6.75 months (range 1.5–9 months), and 38.5% of 
the samples were from patients on long-term ECP and were 
collected after a median of 13 months (range 12–26 months). 
Blood samples from healthy individuals served as control 
where indicated. Peripheral blood from the patients was col-
lected in the context of the University of Zürich Biobank, 
funded by the University of Zurich University Research 
Priority Program (URPP) in translational cancer biology. All 
patients signed an informed consent agreeing to the use sam-
ples, including the generation of cell cultures according to the 
Biobank project (EK No. 647). Blood from healthy individuals 
was obtained anonymously from the blood bank of the 
University Hospital Zurich. The study was conducted in accor-
dance with the principles of the Declaration of Helsinki and 
was approved by the Institutional Review Board of the Canton 
of Zurich (KEK-ZH-No. 2015–0209).
Clinical evaluation and response criteria
Assessment of clinical response to treatment was done according to 
the consensus statement of the International Society for Cutaneous 
Lymphomas (ISCL), the United States cutaneous lymphoma con-
sortium, and the cutaneous lymphoma task force of the European 
Organization for Research and Treatment of Cancer (EORTC).13 
Briefly, patients that reached B0 under therapy were considered in 
complete remission (CR). Partial remission (PR) was defined as 
>50% decrease in quantitative measurements of blood tumor bur-
den from baseline in those with high tumor burden at baseline (B2). 
Progressive disease (PD) was defined as > 50% increase from base-
line and at least 5,000 neoplastic cells/μl blood. Stable disease (SD) 
includes patients that fail to attain criteria for CR, PR, or PD. For the 
current analysis, patients with CR or PR were considered “respon-
ders” and patients with SD or PD as “non-responders” to ECP 
treatment.
Isolation of human peripheral blood mononuclear cells 
(PBMCs) and cell lines
Patient’s peripheral blood mononuclear cells (PBMCs) were 
isolated by Ficoll density gradient centrifugation. Raji, 
a Burkitt’s lymphoma cell line was a kind gift from Prof. 
Magdalena Winiarska, Department of Immunology, Medical 
University of Warsaw.
Flow cytometry
To assess the percentage of NK cells in the collected PBMCs, the 
samples were analyzed by flow cytometry using anti-human 
monoclonal antibodies: CD3 (clone BW264/56, PerCP; 
Miltenyi Biotec #130-096-910), CD4 (Clone VIT4; label APC- 
Vio770; Miltenyi Biotec # 130–098-153), CD8 (clone RPA-T8, 
PE; Beckton Dickinson) and CD56 (clone AF12-7H3, PE- 
Vio770; Miltenyi Biotec #130-096-831). Samples were acquired 
on Becton Dickinson, Allschwil, Switzerland FACSCanto II 
instrument. Flowjo V 10.0.8r1, Becton Dickinson and 
Company, Franklin Lakes, NJ, USA, Origin Pro 2017, 
Northampton, MA, USA and GraphPad Prism 5.0 Software, 
San Diego, CA, USA were used for data analysis and statistics.
Antibody-dependent cellular cytotoxicity assay
To assess NK cell activity in primary human samples, we 
resuspended the PBMCs in 5 ml cRPMI 1640 supplemented 
with 100 IU/ml IL-2 (manufactured by ourselves using human- 
IL-2-transfected J558 cells) and 10 ng/ml Il-15 (#200-15 
Peprotech, Rocker Hill, USA) and incubated them on 6-well 
plates for 24 h (37°C, 5% CO2). After 24 hours, the samples 
were centrifuged (1200 rpm, 3 min RT), resuspended with 
1 mL RPMI 1640, counted, adjusted to a concentration of 
4*106 cells/ml and used in ADCC assay as effector PBMCs. 
For the ADCC assay, cells from the CD20-expressing Raji cell 
line, maintained in cRPMI at 37°C, 5% CO2, were adjusted to 
a final concentration of 2*105 cells/ml and 25 μl of the Raji cell- 
containing solution was seeded on a 96 well plate. 25 μl of the 
anti-human CD20 monoclonal antibody Rituximab (RTX, 
#B6097, Roche, Basel, CH) at a concentration of 300 µg/ml 
(Raji 100), 30 µg/ml (Raji 10) or 0 µg/ml (Raji 0) was added and 
the cells were incubated in 37°C for 15 min to enable surface 
labeling with the antibody. Finally, 25 μl of the effector PBMCs 
(4*106 cells/ml) were added, the plates were centrifuged (3 min, 
750 rpm, RT) and incubated at 37°C, 5% CO2 for 4 hours. The 
cell lysis was quantified by the amount of lactate dehydrogen-
ase (LDH) released into the culture supernatant and measured 
with a commercially available kit according to the manufac-
turer’s instructions (Pierce™ LDH Cytotoxicity Assay Kit; 
88953, ThermoFisher, Waltham, USA). Maximum LDH 
release was determined by lysis in 0.2% Triton X-100. All 
experiments were performed in triplicates. LDH release was 
detected at 490 nm (LDH measurement) and 630 nm (back-
ground) using a microplate reader (ELx808 Absorbance 
Reader; BioTek; Winooski, USA). The effective ADCC in arbi-
trary units (AU) was calculated as the ratio between LDH 
absorption in the presence of 100 µg/ml RTX and in the 
absence of RTX [ADCC [AU] =].
Statistical analysis
Data were tested for normal distribution with Shapiro-Wilk 
test. Dependent on the distribution pattern, Mann Whitney 
test for unpaired, not normally distributed sample groups and 
Wilcoxon matched pairs signed rank test for paired, not nor-
mally distributed sample groups. P values ≤0.05 were consid-
ered significant. Statistical calculations were done on 
GraphPad Prism® 7.01 software.
Results
NK cell numbers are reduced in SS patients compared to 
healthy individuals
In graft-versus-host disease (GvHD) patients for whom ECP 
therapy is commonly used, ECP treatment affects the NK cell 
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compartment,14 and an increase of the CD56bright NK subset is 
predictive of response to treatment.15 To study the role of NK 
cells in the response in SS patients, we first assessed NK cell 
number in peripheral blood of SS patients compared to healthy 
individuals by flow cytometry. At baseline, we detected 
a significant decrease in CD3− and CD56+ NK cell numbers 
(gating strategy shown in Figure 1a) in SS patients with 
a median of 92 cell/µl as compared to healthy individuals 
with a median of 238 cell/µl (p value: 0,00045) (Figure 1b). 
To study the effect of ECP, we compared the NK cell numbers 
at initiation of ECP treatment and after an average of 9 months 
of uninterrupted ECP in a cohort of nine SS patients (Table 1). 
Following ECP, we detected a slight increase of total CD56+ 
NK cells (Figure 1c), as well as of the CD56dim (Figure 1d) and 
CD56bright (Figure 1e) NK cell subsets with great interpatient 
variability. Although we observed a general tendency of recov-
ery of diminished NK cell subsets in SS patients on long-term 
ECP treatment, none of the reported quantitative changes 
reached statistical significance or could be associated with the 
treatment response (Figure 1c-f).
ADCC is enhanced in ECP responders
The quality of the NK cell activity might be a positive response 
predictor for ECP.16 As antibody-dependent cellular cytotoxi-
city (ADCC) is a major effector function of NK cells,17 we 
evaluated its efficacy in SS patients before and after long-term 
ECP treatment. While a standard LDH release assay revealed 
no significant difference in the ADCC efficacy in SS patients at 
baseline (mean 1.087 AU) compared to healthy individuals 
(mean 1.25 AU) (Figure 2a), there was a significant increase 
in the ADCC efficacy in SS patients upon long-term uninter-
rupted ECP treatment (mean 2.28 AU (p = .004) (Figure 2a). In 
general, at a threshold of ≥1.5 AU-fold, the efficacy of ADCC 
was increased in 41.66% (5/12) of all ECP treated SS patients 
(Figure 2b). When stratified according to their clinical 
response to ECP treatment, all but one of the patients with 
increased ADCC upon treatment ≥1.5 AU-fold responded 
clinically, while patients with marginal increase (≤1.3 AU- 
fold) or lack of increase in ADCC activity failed to respond to 
ECP treatment (Figure 2c). Furthermore, the overall level of 
Figure 1. NK cell numbers are reduced in SS compared to healthy and show a tendency of recovery after ECP treatment. (a) Representative FACS plot (left) and 
histogram (right) illustrating the gating strategy on CD3 (y-axis) and CD56 (x-axis) for CD3−/CD56+dim and CD3−/CD56+bright NK cells. (b) Dot plot showing the number of 
NK cells per µl whole blood for healthy individuals (Healthy, n = 12) and Sézary patients (SS, n = 12). (c-e) Dot plots depicting the percentage of NK cells in Sézary 
patients before and after ECP (both groups n = 9), ns = not significant. c) for total CD56+ NK cells (d) for CD56+dim NK cells (e) for CD56+bright NK cells. (f) Bar plots 
depicting the relative changes in NK cells for individual Sézary patients before and after ECP treatment, total CD56+ NK cells (gray), CD56+dim NK cells (green), 
CD56+bright NK cells (blue). Patients with clinical response to treatment are shown as filled bars, those without as empty bars.
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ADCC activity after ECP for non-responders did not differ 
from the ADCC of healthy individuals, but was statistically 
significantly enhanced in SS patients responding clinically to 
ECP treatment (p = .02422) (Figure 2d).
Discussion
ECP is an established and widely used first-line therapy for SS; 
however, predictive factors and biomarkers for monitoring the 
response to treatment are yet largely unknown. NK cells and 
their impact and importance for the mode of action of ECP 
have recently attracted attention, especially in GvHD and 
organ transplant rejections, which together with SS constitute 
the three major approved indications for ECP therapy in 
Switzerland.9,18,19 In CTCL, reduced activity of NK cells has 
been observed, and increased NK cell numbers upon ECP 
treatment have been reported, raising the hypothesis of 
a relative intact immune system being a baseline prediction-
factor of response to ECP.9,20
Here we demonstrate that NK-mediated ADCC is selec-
tively enhanced in ECP responders and might serve as 
a reliable biomarker to objectively monitor response to ECP 
in patients with SS. These findings are strengthened by obser-
vations made in patients with GvHD, where low levels of NK 
cell activity were reported in non-responders and normal NK- 
cell activity before therapy has been proposed as a prognostic 
marker for response.16 We further observed a general tendency 
of recovery of diminished NK cell subsets in SS patients on 
long-term treatment, supporting the casuistically reported 
increase in NK cell numbers in ECP responders.20,21 Further, 
increased NK cells numbers were also detected in one patient 
with immune-checkpoint-inhibitor-induced colitis, positively 
influenced by ECP.22
Based on our findings and supported by the existing knowl-
edge in the literature, we postulate a vital role of NK cells in 
Figure 2. ADCC is enhanced in ECP responders. (a) Boxplots showing the efficacy of antibody-dependent cellular cytotoxicity (ADCC) in arbitrary units (AU) for healthy 
individuals and Sézary patients before and after ECP treatment (Tx), n = 12 for all groups, ns = not significant. A significant increase (p = .004) is detected after ECP 
therapy. (b) Dot plot presenting the same data as in a) for individual Sézary patients, showing great interpatient variability in response to ECP treatment. (c) Bar plots 
showing fold changes in ADCC of Sézary patients after ECP treatment. ECP clinical responders in red, non-responders in black. (d) Box plots showing the efficacy of ADCC 
after ECP in arbitrary units (AU) for healthy individuals and Sézary patients split into non-responders and responders. While the difference in non-reponders in not 
significant (ns), responders show a significant increase (p = .02422) in ADCC compared to healthy.
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shaping efficacy of ECP in SS patients and support the use of 
NK-cell-based therapies for tumor immunotherapy. In general, 
NK cells are seen as a positive factor in the anti-tumor immune 
response and their involvement in immune surveillance has 
been repeatedly demonstrated.17 This study broadens the 
understanding on the role of NK cells’ activity in the context 
of ECP, although the conclusions are limited by the small 
number of patients and their differences in treatment duration 
at the time of sampling ranging between 1.5 and 26 months on 
ECP. Further, we demonstrate enhancement of ADCC, which is 
exerted typically by CD56dim subset. However, as we only report 
trends in the quantitative alterations of these cells, the observed 
increased efficacy may also result from changes in secreted 
cytokines and paracrine stimulation of ADCC-mediating cells. 
Consequently, it will be important for future studies to decipher 
which NK subpopulation – the immature, poorly cytotoxic but 
cytokine-producing CD56bright or the mature, weakly cytokine- 
producing, but cytolytic and thus capable of ADCC, 
CD56dimCD16+ NK cells determine the efficacy of ECP.
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